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Summary 
The presence of natural killer (NK) cells contributes to early defense against murine cytomega- 
lovirus (MCMV) infection. Although NK cells can mediate in vivo protection against MCMV, 
the mechanism by which they do so has not been defined. The studies presented here evaluate 
cytokine production by NK cells activated during MCMV infection and the role of NK cell- 
produced cytokines in early in vivo antiviral defenses. Experiments with normal C57BL/6, 
T  cell-deficient C57BL/6 nude, and severe combined immunodeficient mice lacking T  and B 
cells demonstrated that both interferon ~/(IFN-~/) and tumor necrosis factor (TNF) production 
were induced at early times after infection with MCMV. Conditioned media samples prepared 
with cells from these mice, on day 2 after infection, produced 11-43 pg/million cells oflFN-~ 
and  12-19 pg/million cells  of TNF as evaluated by specific protein enzyme-linked immuno- 
sorbent assays. Studies in the NK- and T  cell-deficient mouse line, E26, in mice that had been 
depleted in vivo of NK cells  by treatment with  antibodies  eliminating NK cells,  anti-asialo 
ganglio-N-tetraosylceramide or anti-NKl.1,  and with populations  of cells that had been de- 
pleted of NK cells by complement treatment with the anti-NK cell antibody, SW3A4, demon- 
strated that NK cells  were solely responsible for the  IFN-~/ but were not required  for TNF 
production. The in vivo absence of NK cells was accompanied by increased viral hepatitis and 
viral replication in both immunocompetent and immunodeficient mice, as well as decreased 
survival time ofimmunodeficient mice. In vivo treatments with antibodies neutralizing IFN-~/ 
demonstrated that this  factor contributed  to  the  NK cell-mediated antiviral defense and re- 
duced the measured parameters of viral defense to levels indistinguishable from those observed 
in NK cell-deficient mice. These effects appeared to be independent  of cytolytic activity, as 
NK cells isolated from anti-IFN-~/-treated mice mediated killing at levels comparable to those 
observed in control-treated mice. The consequences ofinterleukin 12 (IL-12) administration, a 
known potent inducer of IFN-~/production by NK cells, were evaluated in MCMV-infected 
mice. Low IL-12 doses, i.e.,  1 ng/d, increased NK cell cytotoxicity and IFN-~/production up 
to twofold and resulted in improved antiviral status;  virus-induced hepatitis was decreased as 
much as fivefold, and viral burdens were decreased to levels below detection. The beneficial ef- 
fects oflL-12 treatment were prevented by depleting either NK cells or IFN-~/. As infection of 
severe combined immunodeficiency mice was exacerbated by anti-IFN-~/administration and 
benefited from IL-12, the antiviral effects of both administered IL-12 and NK cell-produced 
IFN-'y in vivo could be independent of T  and B  cells.  The results elucidate a cytokine-medi- 
ated mechanism for antiviral function of NK cells in vivo. Furthermore, they demonstrate the 
therapeutic efficacy of IL-12 administration in the context of an acute viral infection. 
M  urine cytomegalovirus (MCMV) I is a herpesvirus with 
.considerable homology to human CMV on both bi- 
ological and molecular levels (1). Acute infection ofimmu- 
nodeficient  or susceptible mice with MCMV  can lead to 
profound hepatitis (2), pneumonia (3), bone marrow toxic- 
ity (4), and multiorgan failure (5). The immune response in 
mice acutely infected with MCMV is characterized by an 
early activation of NK cell cytotoxicity (6) and a later acti- 
1Abbreviations used in  this paper: AGM1, asialo ganglio-N-tetraosylcera- 
mide; LCMV, lymphocytic  choriomeningitis virus; MCMV, murine cy- 
tomegalovirus; mrlL-12, murine rlL-12. 
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infection, respectively. NK  (8-10),  CD4 +  T  (11,  12),  and 
CD8 +  (13)  T  cell responses  have  all been  shown  to  play 
important roles in defense against MCMV  infection. CD8 + 
T  cells mediate MHC  class I-restricted lytic activity and are 
responsible for later peripheral clearance of virus  (13,  14). 
CD4 + T  cells produce IFN-y and TNF, which are respon- 
sible for clearance of MCMV  from sahvary glands (15,  16). 
NK  cells  mediate  protection  by  regulating  viral  load  at 
early times after MCMV  infection (9). 
Although  it is  clear that  NK  cells can  control MCMV 
replication, the  mechanisms  by which  they do  so  are  not 
well understood.  NK  cells may contribute  to  the  in  vivo 
regulation of virus replication by killing infected cells (17). 
They may alternatively or additionally make  cytokines to 
inhibit viral replication. Both IFN-~/and TNF have direct 
antiviral effects on MCMV  replication (18).  Under appro- 
priate conditions, NK cells can be activated to make IFN-y 
and/or TNF  (19).  However,  cytokine production by NK 
cells and a resulting role of any produced cytokines on anti- 
viral states have not yet been examined. 
The studies presented here were undertaken to evaluate 
cytokine production by NK cells activated during MCMV 
infection and to determine the contribution of endogenous 
NK cell cytokine production to regulation of viral replica- 
tion  and  virus-induced  disease.  In  addition  to  evaluating 
the basal expression and function of NK cell-produced cy- 
tokines,  the  therapeutic  effects  of  IL-12  administration 
were  examined.  This  factor was  evaluated because  it has 
been shown to induce IFN-~/and TNF production in vivo 
(20-22), to activate NK cell killing in vitro (23) and in vivo 
(22),  and  to  stimulate  NK  cell production  of IFN-y and 
TNF  in vitro  (24,  25)  (for review see reference 26).  The 
results  of our  studies  conclusively  demonstrate  that  NK 
cells are induced  to  express IFN-~/ during MCMV  infec- 
tion, and that this factor is a major contributor to NK cell- 
mediated protection  against MCMV  infection.  They  also 
show that low-dose IL-12 administration, primarily as a re- 
sult of inducing increased IFN-~/production by NK cells, 
can enhance NK cell-mediated defense against MCMV  in- 
fection. Taken together, the studies define a mechanism for 
antiviral protection mediated by NK cells and demonstrate 
beneficial consequences of IL-12 administration in defense 
against viral infections. 
Materials  and Methods 
Mice.  Specific  pathogen-free  male  C57BL/6  (C57BL/ 
6NTacfBR),  Swiss  athymic  nude  (Tac:N:NIHS-nufDF),  C.B- 
17-SCID  (C.B-17/IcrTac-scidfDF),  and  C57BL/6-NUDE 
(C57BL/6NTac-nufDF  N9)  mice were obtained from Taconic 
Inc.  (Gemlantown,  NY).  Male C57BL/6J  mice  homozygous or 
heterozygous for the nude gene were obtained from The Jackson 
Laboratory (Bar Harbor, ME). All mice were 5-10 wk old when 
used in experiments. The NK- and T  cell-deficient E26 mouse 
line, transgenic for the human CD3e gene, was established as de- 
scribed (27) and bred homozygous for the transgene (+/+) un- 
der strict isolation in our pathogen-free breeding facility at Brown 
University (Providence, RI). The facility is monitored serologi- 
cally by evaluation of control mice. Male and female E26 mice 
were between 6 and 20 wk of age when used in experiments. Vi- 
res- and antibody-free CD-1 (Crl :CD-1 [ICR]BR) mice were ob- 
tained from Charles River Laboratories (Wilmington, MA) to pre- 
pare viral stocks. 
Virus and  Virus Titration.  MCMV  V70  CD1  salivary  gland 
extract was kindly provided by Dr. Mary Jane Selgrade (Environ- 
mental  Toxicology  Division,  U.S.  Environmental  Protection 
Agency, Triangle Park,  NC).  Subsequent  stocks of virus were 
prepared as a  10% (wt/vol) homogenate of salivary glands from 
infected CD-1  or C57BL/6  mice (28).  MCMV was  quantitated 
by  plaque  assay  on  monolayers  of mouse  embryo  fibroblasts. 
MCMV titers were assessed by weighing and homogenizing left 
lateral liver lobes. Duplicate log dilution samples of organ super- 
natants were used to infect mouse embryo fibroblast monolayers, 
which were then overlayed with 1 ￿  medium 199 containing 5% 
heat-inactivated fetal bovine serum,  10,000  U  nystatin (GIBCO 
BRL,  Gaithersburg, MD),  100  U  penicillin/100 Ixg streptomy- 
cin, 2 mM glutamine, and 0.6% low-gelling temperature agarose 
(FMC  Corp.  Bioproducts,  Rockland,  ME).  Cell  monolayers 
were incubated for 4.5  d  at 37~  in 5%  CO 2 and stained with 
0.1% crystal violet in 1% formaldehyde. Virulence of MCMV was 
tested by analyzing hepatic pathology at  2  d  after infection  of 
mice. 
Antibodies  and  Cytokine ELISAs.  Rabbit  polyclonal antibody 
against asialo ganglio-N-tetraosylceramide (AGM1) was obtained 
from  Wako  Chemicals  (Richmond,  VA).  Rabbit  IgG  (Sigma 
Chemical Co., St. Louis, MO) was used as a control. PK136 and 
SW3A4  hybridomas,  producing  a  mouse  IgG2b  specific  for 
NKI.1  (29)  and  lgM  specific for  the  SW3A4  determinant  of 
NKI.1 (30), respectively, were kindly given by Dr. Vinay Kumar 
(Southwestern Medical School, Dallas, TX). Anti-IFN-y XMG1.2 
and isotype control GL113.1  hybridomas were generously pro- 
vided by Dr. Robert Coffman (DNAX Research Institute, Palo 
Alto,  CA).  Filter-sterilized ascites  from  PK136,  control  t}3NS1 
(31), XMG1.2,  and GLl13.1  as well as cell culture supernatants 
from SW3A4 were used. Antibodies were quantitated by specific 
IgG  subclass  ELISA and,  when  appropriate,  were  additionally 
quantified by protein assay (Pierce, Rockford, 1L), flow cytomet- 
ric analysis of binding, and in vivo titration for elimination of cells 
or functions. 
TNF was  quantitated in biological samples  by specific sand- 
wich ELISA as described (21).  1FN-y was detected by sandwich 
ELISA using rat anti-IFN-  3, XMGt .2 as capture reagent and rab- 
bit  anti-mouse  IFN-',/ polyclonal serum  (the  kind  gift  of Dr. 
Philip Scott, University of Pennsylvania, Philadelphia, PA) as de- 
tecting reagent. TNF and IFN-3, standards were from R&I) Sys- 
tems (Minneapolis, MN) or PharMingen (San Diego, CA). Semi- 
tivity of the IFN-y and TNF ELISAs were 39 pg/ml and 19 pg/ 
ml, respectively. 
In  Vivo  Treatment  Protocol.  Murine recombinant IL-12 (mrlL- 
12),  batch number MRB  630717292-A,  specific activity 8.4  ￿ 
106 U/rag with endotoxin contamination <1.8 EU/ml (as mea- 
sured by Limulus amebocyte assay), was  produced by the Mam- 
malian  and  Microbial Cell  Sciences  and  Process  Biochemistry 
groups  of Genetics  Institute,  Inc.  (Cambridge,  MA)  and  was 
kindly provided by Dr. Stanley Wolf. Frozen microgram aliquots 
oflL-12 stock were diluted to 1 ml with 0.4S-Ixm filter-sterilized 
10% C57BL/6  male serum in PBS  at the start of an experiment 
and stored at 4~  for individual experiment durations. Dilutions 
of mrlL-12 used for injections were made from this stock into 
sterile 5% CS7BL/6 male serum in PBS. Animals were given ei- 
ther vehicle or 1 ng mrlL-12 in vehicle the day before infection 
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105 or 4  X  105 PFU MCMV  and again on each day after infec- 
tion until the day before killing. Selection of the 1-ng/d dose of 
IL-12 was based upon dose response experiments in which 0.1,  1, 
10, 100, and 1,000 ng/d were administered, and results were ana- 
lyzed on days  1,  2,  3,  and  5  after infection.  In  survival experi- 
ments, animals were treated with 1 ng mrIL-12 daily until day 5, 
and then every 3 d until death. 
Analyses of the role of NK cells or IFN-~/were performed by 
administration of cell-depleting or neutralizing antibodies the day 
before the first mrIL-12 injection. In day 2 and 3 experiments, an 
additional injection of antibody was given on day  1  after infec- 
tion. To deplete NK cells, 0.5 mg anti-AGM1 or 1 mg of PK136 
was given 1 d  before IL-12 treatment and again before cytokine 
injection on day  1 after infection.  In survival experiments,  0.25 
mg of anti-AGM1 was given on the day before beginning treat- 
ment  and  again on  day 3  after infection.  These  protocols  were 
shown to deplete  >95% of NK cell subsets.  IFN-~/was  neutral- 
ized by administration of 1 mg XMG1.2 the day before first IL- 
12 treatment and 0.25 mg on day 1 after infection. In survival ex- 
periments,  1  mg XMG1.2  was  given the  day  before  treatment 
and 0.5 mg was given every 7 d. All experiments contained paral- 
lel control  groups  that used  rabbit IgG for anti-AGM1,  P3NS1 
for PK136, and GL113.1  for XMG1.2. 
Table  1.  NK Cell Cytotoxicity During MCMV Infection 
Preparation and Evaluation of Biologic Samples.  Splenic  leuko- 
cytes were prepared and cytotoxicity against YAC-1  target cells 
was measured in S~Cr release assay as previously described  (32). 
NK cell populations were measured by flow cytometry based on 
staining of NKI.1 +  CD3-  cells  (33).  Conditioned  media  were 
prepared by 24 h  incubation of 5  ￿  106 splenic leukocytes/ml, in 
ILPMI  1640 medium (GIBCO BILL), supplemented with 2 mM 
glutamine,  100 U  penicillin/100 I.zg streptomycin,  and 1% heat- 
inactivated fetal bovine serum, at 37~  in 5% C02. Where neces- 
sary, supernatants were concentrated 5- to  10-fold using Centri- 
con or Centriprep 10 concentrators (Amicon Inc., Beverly, MA). 
Samples were tested in ELISA for presence of IFN-',/and TNF. 
Results  are  reported as picograms  of cytokine per million cells. 
Limits of detection were "~0.8 pg/million cells and 0.4 pg/mil- 
lion cells for IFN-"/and TNF production, respectively.  In some 
experiments,  NK  cells were  removed from total  splenic leuko- 
cytes  before  preparation  of conditioned  medium  by  treatment 
with  SW3A4  antibody and  rabbit complement  (Pel-Freez  Bio- 
logicals, ILogers, AR). 
Whole  livers were  removed intact from mice  and examined 
for the  presence  of macroscopic  necrotic foci.  A  necrotic focus 
was defined as an isolated region of necrotic liver tissue, I> 1 mm  2, 
that appeared white upon gross examination. Left and right me- 
dian lobes of the liver were prepared for histology by fixation in 
Splenic 
Day after  Number  leukocyte 
Mouse strain  infection  Treatment*  of mice  yield* 
% YAC-1  lysisw 
100 E/T  33 E/T 
C57BL/6  0  None  7  56 +_  1  6.8 
2  Vehicle  12  64 _+ 4  23.6 
IL-12  12  65  +  3  31.8 
3  Vehicle  5  68 _-+- 14  20.2 
IL-12  5  91  _+ 8  19.2 
C.B-17 SCID  0  None  4  12 _+ 2  0.4 
2  Vehicle  3  15 +  4  24.0 
IL-12  3  17 _+  1  39.5 
3  Vehicle  3  17 +  4  42.5 
IL-12  3  11  +- 1  37.0 
C57BL/6 nude  0  None  2  65  _+ 4  11.0 
2  Vehicle  3  66 +  2  42.7 
IL-12  2  44 +  1  61.6 
3  Vehicle  2  71  +  1  47.0 
IL-12  2  78 +- 6  42.5 
E26  0  None  4  76 +-  1  2.4 
2  Vehicle  4  41  +- 8  0.4 
IL-12  5  46 +  6  1.4 
3  Vehicle  4  49  _  9  1.0 
IL-12  6  43  +- 4  0.2 
---  1.9 
-+ 3.4 
+  3.7ql 
--  5.2 
z  3.2 
-+ 0.2 
-+ 4.9 
+  1.6 I 
+-1.1 
-+ 2.8 
-+  1.8 
+- 12.2 
-+ 3,2 ~ 
+-0.1 
-+ 5.6 
+  0.7 
+  0.4 
-+ 0.2 
+- 0.5 
-)- 0.3 
3.7  -  1.5 
13.1  -+ 2.0 
20.6  +  2.0 II 
11.4  -+ 3.6 
11.0  +- 2.2 
0.8 +- 0.3 
13.0 +  4.7 
24.6  -)- 2.2 I 
28.1  -Z-_ 4.9 
26.6  ---  1.0 
3.1  +  1.6 
29.7  --- 8.9 
48.4 +  4.9 I 
34.0 -+ 1.1 
29.8 -+ 7.6 
0.9 +  0.7 
0.6 -- 0.3 
0.8 --- 0.4 
1.0 -+ 0.1 
1.0  +  0.3 
*Mice were treated with 1 ng/d mrlL-12 or vehicle as described in Materials and Methods. 
*Splenic leukocyte yield in millions ofcel/s per spleen --- SE. 
w  lysis as measured in S~Cr release assay +- SE. Data shown were obtained at E/T cell ratios of 100 or 33 to 1. 
IIL-12 treatment mediated significant enhancement conmpared with vehicle control, P <0.05. 
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Control-treated*  IL-12-treated* 
Day after 
Mouse Strain  infection  IFN-~/  TNF  IFN-"/  TNF 
C57BL/6'  0  <0.9 +  0.0 (4)  5.8 +- 1.5 (4)  <0.9w (1)  5.0  .~ (1) 
2  11.2 +  2.9 (5)  12.3 +  1.8 (5)  22.4  +  3.7n (5)  14.2 +  3.4 (5) 
3  1.1  +  0.1 (2)  13.9 +  3.5 (2)  6.9 +  0.1  (2)  19.3 +  5.2 (2) 
C.B-17 SCID~  0  <0.9  4.9  nd  nd 
2  42.6  18.6  100.0  23.4 
3  <0.9  3.5  <0.9  4.1 
E26"*  0  <0.9 +  0.0 (4)  4.1  +  0.4 (4)  nd  nd 
2  <0.9 +  0.1 (3)  10.6 +  0.9 (3)  <0.9 +  0.1  (3)  14.1 +  0.9 (3) 
3  <0.9 __ 0.0 (4)  8.6 +  2.5 (4)  <0.9 +  0.0 (4)  6.0 +  1.2 (4) 
*Values for cytokine production are given in picograms/million cells in culture as explained in Materials and Methods. Where appropriate, values 
are -+ SE. Parentheses identify the number of independent samples tested. All tests were carried out in duplicate. 
*Conditioned media from C57BL/6 mice were prepared either from individual animals or from two or three pooled animals, such that results 
shown were obtained from 5-12 animals  per point. 
w  Point consists of three pooled animals. 
m  lL-I  2 treatment mediated significant  enhancement compared with vehicle control, P <0.05. 
I Conditioned media samples from C.B-17 SCID mice were prepared with cells pooled from three to four animals. 
** Conditioned media samples from E26 +/+ mice were prepared either from individual animals  or from two or three pooled animals  such that re- 
sults shown were obtained from four to eight animals  per point. 
10% buffered formalin.  Paraffin-embedded sections (5 I.tM) were 
prepared,  hematoxylin and eosin stained,  and analyzed  micro- 
scopically. Inflammatory foci were defined as discrete  clusters of 
cells containing between 6 and 60 individual cells. Inflammatory 
foci were quantitated by counting clusters in 8 mm  2 of represen- 
tative liver tissue. 
Statistical Analysis.  Data were analyzed by Student's t test in all 
experiments except survival curves, which were analyzed by Wil- 
coxon signed rank correlation. 
Results 
Induction of NK  Cell-mediated  Cytotoxicity  during MCMV 
Infection and  Effects  of IL-12  Treatment  on  This  Response. 
NK cell activity during MCMV infection of immunocom- 
petent C57BL/6 mice, as measured by cytotoxicity against 
YAC-1 target cells in 51Cr release assay, became apparent at 
day  1  after infection, peaked  on days 3-5  after infection, 
and returned to almost baseline levels by day 7 after infec- 
tion (data not shown). The percentage of NK cells in the 
spleen, as measured by flow cytometry, did not change sig- 
nificantly over the course of infection. Administration of 1 
ng/d IL-12 starting the day before infection did not modify 
the numbers of NK cells or extend the longevity of the NK 
cell response; however, NK cell-mediated cytotoxicity was 
accelerated such that the peak occurred on day 2, instead of 
days  3-5  after  infection (Table  1,  C57BL/6).  Compared 
with  vehicle-treated  controls,  IL-12-treated  mice  had 
A,35-55% greater NK activity on day 2 after infection. 
To isolate the NK cell response from other lymphocyte 
responses,  T  and B  cell-deficient SCID,  T  cell~deficient 
nude, and NK- and T  cell-deficient E26  (27)  mice were 
examined. As in the immunocompetent animals, NK cell 
cytotoxic activity peaked on day 3  after infection in con- 
trol-treated SCID and nude mice, and IL-12 treatment ac- 
celerated NK cell responses in these strains such that peak 
killing was present on day 2 after infection (Table 1, SCID 
and nude). There was an average of~1.5  fold more cyto- 
toxicity in IL-12-treated nude and SCID  mice on  day 2 
than in vehicle-treated controls. In E26 mice deficient for 
both NK and T  cells, NK cell activity was absent on days 2 
and 3  after  infection with  MCMV,  and  IL-12  treatment 
failed  to  induce  significant  cytotoxic  activity  (Table  1, 
E26).  These  observations demonstrate that  administration 
of I  ng/d IL-12 is capable of accelerating NK cell cytotoxic 
responses to  infection in immunocompetent or immuno- 
deficient, but not NK cell-deficient mice. 
Induction of IFN-y and  TNF during MCMV Infection and 
Effects oflL-12  Treatment.  To  measure  early  IFN-y  and 
TNF production during MCMV infection and to  charac- 
terize the effects of IL-12 treatment on these cytokine re- 
sponses,  ex vivo splenic leukocytes were  used to  prepare 
conditioned  media  for  testing  in  ELISAs.  In  C57BL/6 
mice, MCMV infection induced production of both IFN-~/ 
and TNF on day 2 after infection (Table 2, C57BL/6). By 
day 3 after infection, IFN-21 production decreased to mar- 
ginally detectable levels, while TNF production was still at 
induced  levels.  As  increased  TNF  production,  but  not 
IFN-~/production, was present on day 1 after infection, in- 
duction  of  TNF  appeared  to  precede  IFN-~/  (data  not 
shown).  Administration of 1  ng/d IL-12 significantly en- 
hanced the  IFN-~/ response at day 2  after infection; there 
was a twofold increase in IFN-~/production on a per-cell 
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levels.  IL-12  enhancement  of the  day  2  IFN-~  response 
was also evident in T  and B  cell deficient SCID mice. The 
IFN-~/  levels  in  SCID  mice  appeared  higher  than  in 
C57BL/6  mice when  measured  on a  per-cel/basis;  how- 
ever,  there  were  approximately  three-  to  fourfold  fewer 
cells  in the  SCID spleens.  Thus,  levels of IFN-~/ produc- 
tion per spleen  were similar.  These data  demonstrate  that 
IFN-2t and TNF are produced at early times after infection 
with MCMV.  Furthermore,  they show that the IFN-~/re- 
sponse  can  be  significantly increased  by administration  of 
IL-12. 
Role of NK Cells in Cytokine Production.  A  variety  of 
approaches were used to determine  the NK cell contribu- 
tion  to  1FN-~/  and  TNF  production.  First,  responses  in 
NK-  and  T  cell-deficient  E26  mice  were  examined.  In 
contrast to mice with NK cells,  cells from E26 mice did not 
produce IFN-2a during MCMV infection or MCMV infec- 
tion with IL-12 treatment (Table 2, E26). E26 mouse TNF 
responses were comparable to those in NK cell-containing 
mice.  Second,  normal C57BL/6 mice or nude mice were 
NK cell depleted in vitro or in vivo. For in vitro depletion, 
NK cells  were  eliminated  from isolated  splenic  leukocyte 
populations  using  SW3A4  and  rabbit  complement.  In 
C57BL/6 mice either heterozygous or homozygous for the 
nude mutation,  depletion  of NK cells reduced production 
of IFN-~/ (Fig.  1 A). Production of IFN-~/after IL-12 ad- 
ministration  was also  dramatically decreased after  NK cell 
depletion.  In contrast,  elimination  of NK cells did not af- 
fect TNF production  (Fig.  1 B).  In vivo depletion  of NK 
cells  gave equivalent  results.  Cells  isolated  from MCMV- 
infected  C57BL/6  and  C57BL/6  nude  mice  treated  with 
anti-AGM1  or  anti-NKl.1,  to  eliminate  NK  cells,  were 
blocked in IFN-~/production (Fig.  1 C). Likewise,  IFN-~ 
production by cells  from IL-12-treated,  MCMV-infected 
animals was greatly reduced as a result of in vivo NK cell 
depletion.  Induced  TNF  production,  however,  was  ob- 
served  regardless  of the  presence  or  absence  of NK  cells 
(Fig.  1 D).  These results  demonstrate  that the  IFN-~/pro- 
duced at early times after infection with MCMV and/or af- 
ter IL-12 administration at these times is made by NK cells. 
Effects of lL- 12 on MCMV-induced Liver Pathology and Viral 
Replication.  MCMV replicates  to high levels in the liver, 
and antiviral effects can be measured both by viral load and 
virus-induced  pathology at  this  site  (Tables  3  and  4).  Pa- 
thology induced by MCMV infection is characterized by a 
mononuclear cell infiltrate and large areas of hepatic necro- 
sis. Histologically, the cellular inflammation has the form of 
discrete  loci  or  clusters  of cells  present  throughout  the 
liver.  Necrosis is  visualized grossly as small  white  loci  on 
freshly  isolated  livers,  and  histologically  as  large,  discrete 
subcapsular regions ofeosinophilic staining. 
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Figure  1.  Effects of NK cell depletion on IFN-y 
and TNF production in response to MCMV infec- 
tion. Mice were depleted of NK cells either in vitro 
(A and B) or in vivo (C and D). In vitro depletions 
were performed with pooled splenic leukocytes from 
groups of  two C57BL/6 nude/+ or C57BL/6 nude/ 
nude mice on day 3 after infection using SW3A4 and 
rabbit complement (SW3A4). Rabbit  complement 
was used alone as a control (C'). In vivo NK cell de- 
pletions were performed by administration of anti- 
bodies against AGM1 or NKI.1 to groups of two or 
three C57BL/6 and C57BL/6 nude/nude  mice, re- 
spectively. Samples were evaluated for IFN-'y (A and 
C) or TNF (B and D) by ELISA. Error bars shown 
are + SE. 
1049  Orange et al. Table 3.  Effects of lL-12 on Antiviral State in lmmunodeficient Mice 
Hepatic 
Day after  Number of  inflammatory 
Mouse strain  infection  Treatment  mice  loci* 
Hepatic necrotic 
loci per liver:~ 
Log viral 
titer PFU/g 
liver 
C.B-17 SCID  2  Vehicle  4  25  -+ 3  BLD  3.50 
IL-12  5  8  _+  Iw  BLD  <2.07 
3  Vehicle  2  21  +  1  BLD  3.44 
IL-12  2  4  -+ 1  w  BLD  <2.18 
E26  2  Vehicle  3  14  -+ 4  45  -+  10  4.88 
IL-12  3  17  _+ 3  60  _+  13  4.87 
3  Vehicle  3  15  _+  6  19 +  10  5.06 
IL-12  3  22  -+ 1  31  _+  1  5.31 
+  0.10 
_+ 0.09~ 
"4- 0.3O 
-+ 0.18  '~ 
+  0.12 
-+ 0.03 
-+  0.45 
-+ 0.02 
Values are shown -+ SE. 
* Microscopic inflammatory loci are shown per area liver as described in Materials  and Methods. 
*  Macroscopic necrotic loci are shown per whole liver as described in Materials  and Methods. 
w  IL-12 treatment mediated significant decrease  compared to vehicle control P <0.05. 
BLD, below level of detection. 
Table 4.  Effects of lL- 12 on NK  Cell-dependent Antiviral State In  Vivo 
Hepatic 
Day after  Cytokine  Antibody  Number  inflammatory 
Mouse strain  infection  treatment  treatment  of mice  foci 
Hepatic necrotic 
loci per liver 
Log viral titer 
PFU/g liver 
C57BL/6  0  None  None  8  0  +  0 
2  Vehicle  Control  3  69  4-  12 
IL-12  Control  3  22  _+  9* 
Vehicle  Anti-AGM1  3  33  _+ 3 
IL-12  Anti-AGM1  3  37  +  5 
2  Vehicle  Control  3  31  _+  5 
IL-12  Control  3  13  +  1" 
Vehicle  PK136  3  18  _+  5 
IL-12  PK136  3  8  _+  1 
3  Vehicle  5  56  _+ 9 
IL-12  5  14 _+ 4* 
C57BL Nu/Nu  2  Vehicle  Control  3  43  _+ 21 
IL-12  Control  2  26  +  6 
Vehicle  PK136  2  21  _+  1 
IL-12  PK136  3  24  _+  15 
3  Vehicle  2  37 _+  l 
IL-12  2  14 _+ 4* 
0  +  0 
8+5 
0  +  0* 
49 +  21 
51  _+29 
33_+6 
1_+1" 
46  -  17 
14  _+  10 
7_+4 
1+4 
BLD 
BLD 
BLD 
BLD 
BLD 
BLD 
0.0O 
4.78 
4.26 
5.24 
5.00 
4.63 
3.78 
5.32 
4.79 
4.30 
BLD 
4.99 
4.23 
5.27 
4.84 
3.95 
2.34 
--+ 0.0O 
2  0.13 
+  0.13 
-+ 0.02* 
_+ 0.31* 
_+  0.16 
_  0.02* 
+  0.10' 
+  0.06* 
+  0.13 
<2.00* 
-  0.09 
+  0.04* 
_  0.20* 
_  0.12 
-+ 0.44 
--+ 0.18" 
Values are shown +  SE. 
* IL-12 treatment mediates significant decrease compared with vehicle control, P <0.05. 
*NK cell depletion causes significant increase relative  to appropriate control, P <0.05. 
BLD, below level of detection. 
1050  Role of IFN-',/in NK Cell-mediated Antiviral Effects IL-12 treatment significantly inhibited  the  development 
of both pathology and viral replication in the liver. On days 
2  and  3  after  infection,  IL-12-treated  SCID  mice  had 
>80% reductions in numbers of inflammatory foci per area 
liver  and  >1  log decreases  in  hepatic  viral  replication  to 
levels below detection (Table 3, SCID). Because gross ne- 
crotic  loci were not detectable  in MCMV-infected  SCID 
mice,  there  appeared  to  be  a  strain-dependent  genetic 
component to the development of this pathological mani- 
festation.  IL-12 treatment of immunocompetent C57BL/6 
and  T  cell-deficient  C57BL/6  nude  mice also  resulted  in 
decreased hepatitis and viral replication (Table 4). By day 3 
after infection in these mice, numbers of inflammatory foci 
were decreased by >60% and viral replication was reduced 
>1.5  logs.  In C57BL/6  mice,  necrotic  foci were  present 
during MCMV infection and decreased by >75% after IL- 
12  treatment.  These  data  demonstrate  that,  at  early times 
after infection, IL-12 treatment of mice possessing NK cells 
enhances the antiviral state. 
Requirement  for  NK  Cells  in  IL-I2  Enhancement  of the 
Antiviral  State.  To examine the role of NK cells in IL-12- 
mediated enhancement of antiviral responses, NK cell-de- 
ficient mice were evaluated. NK- and T  cell-deficient E26 
mice  displayed  both  inflammatory  and  necrotic  foci  on 
days 2  and 3  after infection  (Table  3, E26).  The develop- 
ment  of hepatitis in these  mice correlated with  high level 
viral  replication  in the liver  (Table  3,  E26).  Treatment  of 
E26 mice with 1 ng/d IL-12 did not alter either the pathol- 
ogy or viral replication in the liver (Table 3, E26).  In im- 
munocompetent C57BL/6 or C57BL/6 nude mice, deple- 
tion of NK cells with anti-AGM1 or anti-NKl.1  antibodies 
abolished the beneficial effects oflL-12 administration (Ta- 
ble  4).  These  data  demonstrate  that  IL-12-mediated  en- 
hancement of early antiviral states in irnmunocompetent or 
immunodeficient mice requires NK cells. 
To determine if the IL-12-mediated enhancement of the 
antiviral  state  had  long-term  benefits  in  immunodeficient 
mice,  survival  experiments  were  performed.  In these  ex- 
periments,  animals were treated with  1 ng/d IL-12 on the 
day before infection, through day 5 after infection, and ev- 
ery 3  d  thereafter.  In NK cell-possessing SCID  and nude 
mice, IL-12 significantly extended life span by r  (Fig. 
2, A  and B). In contrast, IL-12 administration to NK cell- 
deficient E26  mice had no  effect on their  survival  (Fig.  2 
C).  IL-12 treatment  also had no beneficial  effect in nude 
mice depleted of NK cells by anti-AGM1 treatment (Fig. 2 
B).  These observations demonstrate  that IL-12 administra- 
tion  is  able  to  prolong survival  in  immunodeficient  mice 
and that this process is NK cell dependent. 
Requirement  for  NK  Cell-produced  IFN-T  in  Protective 
Antiviral  Responses.  To  determine  the  importance  of NK 
cell-produced IFN-~/in defense against MCMV infection, 
effects  of administration  of the  specific  neutralizing  anti- 
IFN-',/ mAb XMG1.2  were  contrasted  with  those  of the 
isotype-matched  nonspecific  control  antibody  GLl13.1. 
Anti-IFN-y did not significantly alter the induced NK cell 
cytotoxicity against YAC-1 target cells (Fig. 3). Anti-IFN-y 
also did not affect TNF production nor the ability of cells 
to produce IFN-~ when production was measured ex vivo 
(data not shown).  Treatment  with anti-IFN-y did signifi- 
cantly inhibit the antiviral state.  C57BL/6 mice given anti- 
IFN-y had exacerbated parameters of vires-induced pathol- 
ogy; there were sevenfold more necrotic loci and twofold 
more  inflammatory  foci  in  anti-IFN-~/-treated  as  com- 
pared  with  control-treated  mice  on  day  3  after  infection 
(Table  5).  Anti-lFN-~/treatment  also resulted in a log in- 
crease in viral titers at day 3 after infection. The role of NK 
cell-produced IFN-y was specifically examined using SCID 
mice. As in immunocompetent mice, anti-IFN-y decreased 
the  antiviral  state  in  SCID  mice,  evidenced  by  1  log in- 
creased viral replication on day 3  after infection (Table  5). 
Interestingly,  viral replication  in anti-IFN-'y-treated mice 
was  indistinguishable  from that  in  NK  cell-depleted  ani- 
mals (Table 4). These data show that IFN-~/is a major con- 
tributor  to  antiviral  effects  mediated  by  NK  cells  during 
MCMV infection. 
To evaluate the importance of IFN-y production in en- 
hanced  NK  cell-mediated  defense  after  IL-12  treatment, 
anti-lFN-~  was given to mice that were cytokine treated 
and MCMV infected. Similar to depletion of NK cells  (Ta- 
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Figure  2.  Effects  oflL-12 on sur- 
vival of MCMV-infected immun- 
odeficient  mice.  (A)  C.B-17 
SCID, (B) athymic nude, and (C) 
E26 mice were treated with 1 rig/ 
d IL-12 (,,(~,,) or vehicle (-{~-) as 
described in Materials and Meth- 
ods. Nude mice were given either 
antibody against AGM1 (-~-) or 
control rabbit lgG in addition to 
cytokine on the day before infec- 
tion and on day 3 after infection 
(B). All experimental groups con- 
tained between five and seven ani- 
mals. Prolongation of  life span me- 
diated by IL-12 administration was 
significant compared with vehicle- 
treated controls in both SCID and 
athymic nude mice (P =  0.03 and 
0.06, respectively). 
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Figure 3.  Effects ofand-lFN-~/treatment on NK cell cytotoxic activity. 
Mice  were  antibody  treated  with  either  XMG1.2  anti-IFN-y  or 
GLl13.1 isotype  control on the day before infection and on day  1 after 
infection. Cytotoxic activity  of splenic leukocytes against YAC-1  target 
cells was evaluated on day 3 after infection in SlCr release assays. Groups 
contained three animals each, and error bars shown are +  SE. The differ- 
ence between the XMG1.2 or GL113.1  data points at respective  E:T ra- 
tios is not of statistical significance. 
ble  4),  the  beneficial  effects  of IL-12  treatment  were  ab- 
lated by in vivo neutralization of IFN-~/.  In IL-12-treated 
C57BL/6  mice  given anti-IFN-y,  both hepatitis and viral 
replication  were  increased;  there were  threefold  more  in- 
flammatory  foci,  10-fold  more  necrotic  foci,  and almost a 
2-log increase in viral titer in IL-12-treated mice receiving 
anti-IFN-~/as compared with IL-12-treated controls (Table 
5,  C57BL/6).  The  antiviral effects of IL-12  in SCID  mice 
were  also  prevented  by  anti-IFN-y  treatment  (Table  5, 
SCID).  Viral titers in all of the anti-IFN-~/-treated animals 
were similar whether or not they received IL-12.  These re- 
sults  demonstrate  that  the  IL-12-induced  increase  in  NK 
cell-mediated antiviral function is dependent  upon  IFN-~/. 
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Figure 4.  Effects of anti-IFN-y administration on survival of MCMV- 
infected, IL-12-treated nude mice. Athymic nude mice were treated with 
1 ng/d IL-12 or vehicle as described in Materials and Methods. The anti- 
IFN-  3,  antibody, XMG1.2,  or isotype  control antibody, GLl13.1,  was 
administered on the day before treatments began and on day 5 after infec- 
tion. Groups contained six animals each.  Prolongation of life span medi- 
ated by IL-12 treatment was significant  (P =  0.02)  compared with vehi- 
cle-treated  controls.  Decrease  of  life  span  mediated  by  anti-lFN-'y 
treatment was significant in vehicle-treated (P =  0.06) and IL-12-treated 
mice (P =  0.03). 
Experiments were carried out to analyze the importance 
of NK  cell-produced  IFN-y  in survival after MCMV  in- 
fection of immunodeficient  nude mice.  Similar to NK  cell 
depletion  (Fig.  2),  anti-IFN-y  treatment of nude mice  re- 
suited in >20%  reduction of life span (Fig. 4). Prolongation 
of life  induced  by  IL-12  treatment  was  prevented  by  ad- 
ministration  of  anti-IFN-~/  antibodies,  and  anti-IFN-y- 
treated mice died at similar days after infection regardless of 
Table 5.  Inte~Ceron-T-mediated  Antiviral State During MCMV Infection: Mechanism  for Endogenous and IL- 12-Induced Protection 
Hepatic  Hepatic necrotic  Log viral titer 
inflammatory foci  loci per liver  PFU/g liver 
Day after 
Mouse strain  infection  Treatment  Control  Anti-IFN-3,  Control  Anti-IFN-3,  Control  Anti-IFN-~/ 
C57BL/6  2  Vehicle  61  -+ 13  74 -+  13  35  +  14  98  +  34*  5.18 _+-+ 0.06  5.43  +  0.02* 
[L-12  33  +  7  73  +  3*  7  _+  1'  59  +  11"  4.33  -+ 0.10'  5.47  +- 0.10" 
3  Vehicle  77 +  l  140  --- 8*  9  +  7  69  +  25*  5.05  +  0.06  5.90 +_ 0.16" 
IL-12  34 _+ 3*  110 +  16"  3  _  1'  38 -- 4*  4.03  +  0.09*  5.73  _+ 0.15" 
C.B-17 SCID  2  Vehicle  37  +  5  50 +  2*  BLD  BLD  4.87  +  0.15  5.23  +  0.08* 
IL-12  23 +  25  46  _+ 5*  BLD  BLD  4.24 .+ 0.09*  5.14  +  0.05* 
3  Vehicle  71  .+ 4  99 _+ 8  BLD  BLD  4.65  +  0.04  5.64 .+ 0.09* 
[L-12  30  ,+ 2  88 -+_ 5  BLD  BLD  3.89 .+ 0.14*  5.52 -+ 0.05* 
Values shown represent three mice per group +  SE. 
* Administration of anti-tFN-~/neutralizing antibodies causes significant increase relative to appropriate control, P <0.05. 
~: IL-12 treatment mediates significant enhancement compared with vehicle control, P <0.05. 
1052  Role of IFN-y in NK Cell-mediated Antiviral Effects IL-12  treatment  (Fig.  4).  These  results  demonstrate  that 
NK cell-produced IFN-y is important to the longevity of 
immunodeficient animals and that beneficial effects of IL- 
12 require IFN-y. Taken together with the studies on early 
viral  load  and  virus-induced  pathology,  they  show  that 
IFN-y regulation of MCMV replication can be enhanced 
by IL-12 administration. 
Discussion 
The studies presented here prove the biological impor- 
tance  of NK  cell-produced IFN-y in protective antiviral 
responses, demonstrate conditions under which IL-12 can 
be used therapeutically during a viral infection, and identify 
NK cell-dependent production of IFN-y as a mechanism 
for IL-12-induced antiviral effects. To our knowledge, this 
is  the  first  demonstration  of the  importance  of cytokine 
production exclusively by NK  cells  in  protection against 
viral infection and the therapeutic efficacy of IL-12 during 
a viral infection. 
Demonstration of a role for NK cell-produced IFN-y in 
defense  against  MCMV  infection  complements  and  ex- 
tends work from others demonstrating the  following:  (a) 
that IFN-y can directly inhibit MCMV replication in cell 
culture (15, 18, 34), and (b) that this factor is important for 
late protective T  cell responses to MCMV  infection (15, 
35). Our experiments show that NK cell-produced IFN-y 
regulates MCMV replication and MCMV-induced pathol- 
ogy in both immunocompetent and immunodeficient mice 
(Table 5),  and it contributes to the establishment of mean 
survival times in T  cell-deficient mice (Fig.  4).  Thus, our 
studies extend the characterization of the role of IFN-y in 
protection against  MCMV infection to early times after in- 
fection preceding T  cell responses or in the absence of T 
ceHs. 
Taken together with the earlier culture studies (18,  34), 
our  results  are  consistent  with  a  model  whereby  IFN-y 
mediates protection by directly inhibiting MCMV replica- 
tion  in  infected cells.  Furthermore,  although  the  studies 
presented here do not directly examine a role for TNF in 
the antiviral effects, they do demonstrate that TNF is being 
produced at times of IFN-y production (Table 2 and Fig. 
1). As others have shown that TNF can also act alone and/ 
or in synergism with IFN-y to inhibit MCMV replication 
in  culture  (18),  IFN-y  may synergize with  this  factor at 
early times  during  infection to  directly regulate  MCMV 
replication in  vivo.  IFN-y  can also  activate macrophages 
(36),  and activated macrophages have increased TNF pro- 
duction (37).  Although it is possible that IFN-y also  may 
be  amplifying TNF  production  in  vivo,  our  data  on  ex 
vivo production of TNF by cells isolated from anti-IFN- 
y-treated mice suggest that  this  does not  explain the  in- 
duced levels of TNF detected (see  Results).  However, as 
IFN-y has also been shown to increase sensitivity to TNF 
(38),  this  factor might  alternatively enhance  antiviral  de- 
fenses by increasing  endogenous  cell sensitivity to  TNF. 
Thus, the antiviral effects of NK cell-produced IFN-~/may 
be a result of in vivo synergism between TNF and IFN-y. 
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The role of NK cells in defense against MCMV has been 
previously established through a variety of independent ap- 
proaches. First,  endogenous NK cell cytotoxic activity cor- 
relates  with  resistance  to  MCMV  infection  (6).  Second, 
beige mutant mice with defective NK cells are more sus- 
ceptible to lethal MCMV infection (8). Third, in vivo de- 
pletion  of NK  cells  by antibody treatment  results  in  in- 
creased sensitivity to MCMV infection (9,  10).  Thus, the 
evidence supporting the role of NK cells in defense against 
MCMV  infection is persuasive.  It has long been assumed 
that the mechanism for NK cell-mediated defense is lysis of 
infected cells.  However,  there  are  limited  studies  testing 
this hypothesis and no clear in vivo data to support it.  In 
vitro  experiments  testing  sensitivity  of MCMV-infected 
target cells to NK cell-mediated lysis have resulted in con- 
flicting results.  In contrast with normal cells,  MCMV-in- 
fected fibroblasts have only moderate to low sensitivity to 
NK cell-mediated cytotoxicity, but they do not acquire re- 
sistance  to NK cell-mediated lysis upon exposure to IFN-[3 
(17).  These  results have  been  interpreted to  suggest  that 
NK cells can specifically kill  MCMV-infected cells in the 
presence  of in  vivo  IFN-ce/J3,  but  the  pathway  has  not 
been conclusively demonstrated in vivo. Although chemi- 
cal induction of NK cell activity has been associated with 
enhanced  survival  after MCMV  infection  (39),  it  is  not 
clear if any other parameters of NK cell or cytokine re- 
sponses are altered by this treatment. Even if some of the 
NK  cell-mediated effects against  MCMV  infection are  a 
consequence  of infected  cell  lysis,  the  studies  presented 
here definitively show that IFN-y is a major contributor to 
NK  cell-mediated defense against  MCMV.  The  IFN-y- 
mediated effect does not appear to be a result of induction 
of NK cell-mediated lysis (Fig. 3). Although it is not possi- 
ble  to  rule  out  IFN-y-dependent  changes  in  target  cell 
range or in vivo NK cell trafficking, our results  are consis- 
tent  with  the  earlier  observation  that  administration  of 
IFN-y can substitute for NK cells in defense against mor- 
tality  (40).  They  suggest  that  NK  cell-produced  IFN-y 
mediates protection through  mechanisms  independent  of 
target cell lysis. 
Activation of NK cell cytotoxic activity and IFN-y pro- 
duction correlated during MCMV infection, but this may 
not  be  the  NK  cell  response  to  all  viral  infections.  Al- 
though we have conclusively demonstrated IFN-y mKNA 
expression by a proportion of NK cells activated to mediate 
elevated killing at early times after infection with lympho- 
cytic  choriomeningitis  virus  (LCMV)  (41,  and  Salazar- 
Mather, T., R.. Ishikawa, and C. A. Biron, manuscript sub- 
mitted  for publication),  we  have  been  unable,  using  the 
methods presented in this report, to demonstrate detectable 
IFN-y  protein  production  by LCMV-induced  NK  cells 
(Orange, J.  S., and C. A. Biron, manuscript submitted for 
publication).  It  is  interesting  to  note  that,  although  NK 
cells are important in defense against MCMV, they have no 
demonstrable  role  in  controlling  early  LCMV  infection 
(42,  43). Thus, the induction of NK cell lytic activity and 
NK  cell-mediated antiviral  effects do  not  correlate.  Our 
studies in LCMV as compared with the MCMV infection suggest that there is an association between IFN-',/produc- 
tion  by NK  cells and  NK  cell-mediated  defense  against  a 
virus. 
The  question  of why NK cells are activated  to mediate 
killing  and  produce  IFN-y  in  response  to  MCMV  infec- 
tion arises from our results.  This could be the  result  of ei- 
ther the presence of additional  activation signals (i.e.,  and/ 
or  the  absence  of negative  signals).  We  are  currently  ex- 
ploring this  question  in depth.  The  studies presented  here 
show  NK  cell-independent  production  of TNF  (Table  2 
and Fig.  1). A distinguishing feature of MCMV  infection is 
that  macrophages,  in  particular,  are  targeted  by  the  virus 
(44). Direct infection of macrophages most likely results in 
their  early activation  and  accounts  for the  rapid  TNF  in- 
duction.  MCMV  infection  of macrophages  has  also  been 
shown  to  result  in  IFN-od[3  production  (45),  and  these 
factors are known  to activate NK  cell killing  (46,  47)  but 
are  poor  inducers  of  cytokine  production  by  NK  cells 
(Biron,  C.  A.,  unpublished  results).  As  macrophages  can 
also be an excellent source oflL-12  (48) and this factor can 
activate  IFN-y  production  by  NK  cells  (26,  49-50), 
MCMV  infection  of macrophages may elicit an  IL-12 re- 
sponse  to  induce  NK  cell  production  of IFN-%  Recent 
evidence from our laboratory shows that IL-12 is produced 
in response to MCMV  infection and proves that this factor 
is  necessary  for  the  day  2  IFN-~/  production  during 
MCMV  infection  (Orange, J.  S.,  and  C.  A.  Biron,  manu- 
script submitted for publication).  Thus,  there appears to be 
cooperation  between  NK  cells  and  macrophages  at  early 
times during MCMV  infection  to create a protective anti- 
viral state. 
Administration  of 1 ng/d IL-12 enhanced antiviral states 
(Tables 3  and 4,  and Fig.  2).  The  enhanced  antiviral states 
were shown to be dependent  upon NK cell production  of 
IFN-"/  (Table  5  and  Fig.  4).  The  dose  of IL-12 used  was 
critical for achieving enhanced protection.  Higher doses of 
IL-12 either had no effect (10-100  ng/d)  or had detrimen- 
tal  effects  (>100  ng/d)  (Materials  and  Methods,  and  data 
not  shown).  We  have  previously  shown  that,  during 
LCMV infection, doses oflL-12 in excess of 100 ng/d syn- 
ergize  with  the  endogenous  immune  response  to  induce 
systemic  TNF  (20,  21).  A  consequence  of the  systemic 
TNF  production  is the  elimination  of responding  CD8 + 
T  cells (21). As this population is responsible for viral clear- 
ance, there is also a resulting increase in viral burden.  In con- 
trast, low doses (1 ng/d)  significantly enhance CD8 + T  cell 
responses  to  either  LCMV  or  MCMV  (20).  The  studies 
presented here demonstrate that low doses can be beneficial 
in  enhancing  early  responses  to  MCMV  infection.  They 
underscore  the  importance  of  evaluating  administration 
dose in the context of an ongoing endogenous immune re- 
sponse. 
Our studies have used the genetically altered E26 mouse 
line. These mice are stabily deficient in both NK and T  cells 
(27).  The experiments presented here are the first evaluat- 
ing  the  use  of these  mice  as  a  vehicle  for examining  NK 
cell-mediated effects in vivo. The results demonstrate that, 
during MCMV  infection,  the NK cell-mediated  functions 
of cytotoxicity  (Table  1)  and IFN-~ production  (Table  2) 
are missing in these animals. Because the E26 mice are in- 
duced to express TNF  (Table 2), however, they are clearly 
responding  to  the  viral challenge.  IL-12 treatment  of E26 
mice did not induce NK cell-mediated functions  (Tables 1 
and  2),  nor  did  it  induce  an  antiviral  state  in  these  mice 
(Table  3  and  Fig.  2).  In all parameters  evaluated,  the  E26 
mice  responses  were  comparable  to  those  of nude  mice 
rendered  NK cell  deficient by in vivo antibody  treatment 
(Table 4 and Fig. 2). E26 mice have an advantage over the 
antibody-treated  mice because  they  are  rendered  NK  cell 
deficient in a complete and long-term manner as a result of 
their genetic manipulation. 
In conclusion, by using NK cell-deficient mice and anti- 
body-mediated neutralization of IFN-~/in vivo, the studies 
here demonstrate  a  cytokine-mediated  mechanism for NK 
cell defense  against viral infection.  In addition,  they show 
that IL-12 can be effectively used as a therapeutic  agent to 
enhance this antiviral pathway.  The results suggest that the 
contribution  of an  NK  cell-mediated  component  of de- 
fense  against  viral  infection  may require  the  induction  of 
IFN-',/production  by NK cells in addition  to,  or as an al- 
ternative to, the activation of NK cell-mediated cytotoxicity. 
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